Initial Despair and Current Hope of Identifying a Clinically Useful Treatment of Myocardial Reperfusion Injury: Insights Derived from Studies of Platelet P2Y Antagonists and Interference with Inflammation and NLRP3 Assembly

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 May 25

PMID 38791515

Authors

Michael V Cohen

James M Downey

Affiliations

Soon will be listed here.

Abstract

Myocardial necrosis following the successful reperfusion of a coronary artery occluded by thrombus in a patient presenting with ST-elevation myocardial infarction (STEMI) continues to be a serious problem, despite the multiple attempts to attenuate the necrosis with agents that have shown promise in pre-clinical investigations. Possible reasons include confounding clinical risk factors, the delayed application of protective agents, poorly designed pre-clinical investigations, the possible effects of routinely administered agents that might unknowingly already have protected the myocardium or that might have blocked protection, and the biological differences of the myocardium in humans and experimental animals. A better understanding of the pathobiology of myocardial infarction is needed to stem this reperfusion injury. P2Y receptor antagonists minimize platelet aggregation and are currently part of the standard treatment to prevent thrombus formation and propagation in STEMI protocols. Serendipitously, these P2Y antagonists also dramatically attenuate reperfusion injury in experimental animals and are presumed to provide a similar protection in STEMI patients. However, additional protective agents are needed to further diminish reperfusion injury. It is possible to achieve additive protection if the added intervention protects by a mechanism different from that of P2Y antagonists. Inflammation is now recognized to be a critical factor in the complex intracellular response to ischemia and reperfusion that leads to tissue necrosis. Interference with cardiomyocyte inflammasome assembly and activation has shown great promise in attenuating reperfusion injury in pre-clinical animal models. And the blockade of the executioner protease caspase-1, indeed, supplements the protection already seen after the administration of P2Y antagonists. Importantly, protective interventions must be applied in the first minutes of reperfusion, if protection is to be achieved. The promise of such a combination of protective strategies provides hope that the successful attenuation of reperfusion injury is attainable.

References

Soehnlein O, Libby P . Targeting inflammation in atherosclerosis - from experimental insights to the clinic. Nat Rev Drug Discov. 2021; 20(8):589-610. PMC: 8112476. DOI: 10.1038/s41573-021-00198-1. View

Ye R, Jneid H, Alam M, Uretsky B, Atar D, Kitakaze M . Do We Really Need Aspirin Loading for STEMI?. Cardiovasc Drugs Ther. 2022; 36(6):1221-1238. DOI: 10.1007/s10557-022-07327-x. View

Tong D, Quinn S, Nasis A, Hiew C, Roberts-Thomson P, Adams H . Colchicine in Patients With Acute Coronary Syndrome: The Australian COPS Randomized Clinical Trial. Circulation. 2020; 142(20):1890-1900. DOI: 10.1161/CIRCULATIONAHA.120.050771. View

Rischard F, McKean T . Ischemia and ischemic preconditioning in the buffer-perfused pigeon heart. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998; 119(1):59-65. DOI: 10.1016/s0742-8413(97)00182-5. View

Sandanger O, Ranheim T, Vinge L, Bliksoen M, Alfsnes K, Finsen A . The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury. Cardiovasc Res. 2013; 99(1):164-74. DOI: 10.1093/cvr/cvt091. View

Patti G, Barczi G, Orlic D, Mangiacapra F, Colonna G, Pasceri V . Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (Antiplatelet therapy for Reduction of.... J Am Coll Cardiol. 2011; 58(15):1592-9. DOI: 10.1016/j.jacc.2011.06.044. View

Broch K, Anstensrud A, Woxholt S, Sharma K, Tollefsen I, Bendz B . Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2021; 77(15):1845-1855. DOI: 10.1016/j.jacc.2021.02.049. View

Wang L, Hauenstein A . The NLRP3 inflammasome: Mechanism of action, role in disease and therapies. Mol Aspects Med. 2020; 76:100889. DOI: 10.1016/j.mam.2020.100889. View

Bonora M, Giorgi C, Pinton P . Molecular mechanisms and consequences of mitochondrial permeability transition. Nat Rev Mol Cell Biol. 2021; 23(4):266-285. DOI: 10.1038/s41580-021-00433-y. View

10.

Yue R, Lu S, Luo Y, Wang T, Liang H, Zeng J . Calpain silencing alleviates myocardial ischemia-reperfusion injury through the NLRP3/ASC/Caspase-1 axis in mice. Life Sci. 2019; 233:116631. DOI: 10.1016/j.lfs.2019.116631. View

11.

Lin J, Lai X, Fan X, Ye B, Zhong L, Zhang Y . Oridonin Protects against Myocardial Ischemia-Reperfusion Injury by Inhibiting GSDMD-Mediated Pyroptosis. Genes (Basel). 2022; 13(11). PMC: 9690185. DOI: 10.3390/genes13112133. View

12.

Murry C, Jennings R, Reimer K . Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986; 74(5):1124-36. DOI: 10.1161/01.cir.74.5.1124. View

13.

Xiao H, Li H, Wang J, Zhang J, Shen J, An X . IL-18 cleavage triggers cardiac inflammation and fibrosis upon β-adrenergic insult. Eur Heart J. 2017; 39(1):60-69. DOI: 10.1093/eurheartj/ehx261. View

14.

Hahn J, Song Y, Kim E, Yu C, Bae J, Chung W . Ischemic postconditioning during primary percutaneous coronary intervention: the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction (POST) randomized trial. Circulation. 2013; 128(17):1889-96. DOI: 10.1161/CIRCULATIONAHA.113.001690. View

15.

Hearse D, Humphrey S, CHAIN E . Abrupt reoxygenation of the anoxic potassium-arrested perfused rat heart: a study of myocardial enzyme release. J Mol Cell Cardiol. 1973; 5(4):395-407. DOI: 10.1016/0022-2828(73)90030-8. View

16.

Suetomi T, Willeford A, Brand C, Cho Y, Ross R, Miyamoto S . Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca/Calmodulin-Dependent Protein Kinase II δ Signaling in Cardiomyocytes Are Essential for Adverse Cardiac Remodeling. Circulation. 2018; 138(22):2530-2544. PMC: 6309790. DOI: 10.1161/CIRCULATIONAHA.118.034621. View

17.

Hausenloy D, Boston-Griffiths E, Yellon D . Cyclosporin A and cardioprotection: from investigative tool to therapeutic agent. Br J Pharmacol. 2011; 165(5):1235-45. PMC: 3372712. DOI: 10.1111/j.1476-5381.2011.01700.x. View

18.

Yang X, Liu Y, Cui L, Yang X, Liu Y, Tandon N . Platelet P2Y₁₂ blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther. 2012; 18(3):251-62. PMC: 3625463. DOI: 10.1177/1074248412467692. View

19.

Silvis M, Demkes E, Timmers L, Arslan F, de Jager S, Sluijter J . NLRP3-Inflammasome Inhibition with IZD334 Does Not Reduce Cardiac Damage in a Pig Model of Myocardial Infarction. Biomedicines. 2022; 10(12). PMC: 9775177. DOI: 10.3390/biomedicines10123056. View

20.

Audia J, Yang X, Crockett E, Housley N, Haq E, ODonnell K . Caspase-1 inhibition by VX-765 administered at reperfusion in P2Y receptor antagonist-treated rats provides long-term reduction in myocardial infarct size and preservation of ventricular function. Basic Res Cardiol. 2018; 113(5):32. PMC: 6396295. DOI: 10.1007/s00395-018-0692-z. View